Go to
current issue
-
Making sense of multiorgan MRI imaging for post-acute sequelae of SARS-CoV-2 infection Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-22 Matthew R Baldwin
Abstract not available
-
Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-22
Introduction The multiorgan impact of moderate to severe coronavirus infections in the post-acute phase is still poorly understood. We aimed to evaluate the excess burden of multiorgan abnormalities after hospitalisation with COVID-19, evaluate their determinants, and explore associations with patient-related outcome measures. Methods In a prospective, UK-wide, multicentre MRI follow-up study (C-MORE)
-
Air pollution, climate change, and lung health in Europe Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-20
Abstract not available
-
COVID-19 boosters versus primary series: update to a living review Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-15 Nana Wu, Keven Joyal-Desmarais, Ariany Marques Vieira, Comfort Sanuade, Mohit Jagwani, Laurence Paquet, Paula A B Ribeiro, Jovana Stojanovic, Doro Yip, Simon L Bacon
Abstract not available
-
Progress and challenges in tuberculosis control in Sudan Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-15 Yassir Adam Shuaib, Nuha Yousif Ibrahim, Rasheeda Hamid Abdalla, Mohamed Abdelsalam Abdalla, Amel Omer Bakhiet, Hamdan Mustafa Hamdan
Abstract not available
-
Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-13 Gustavo H Dayan, Nadine Rouphael, Stephen R Walsh, Aiying Chen, Nicole Grunenberg, Mary Allen, Johannes Antony, Kwaku Poku Asante, Amit Suresh Bhate, Tatiana Beresnev, Matthew I Bonaparte, Médéric Celle, Maria Angeles Ceregido, Lawrence Corey, Dmytro Dobrianskyi, Bo Fu, Marie-Helene Grillet, Maryam Keshtkar-Jahromi, Michal Juraska, Jia Jin Kee, Nianxian Zhang
Background COVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern. This study aimed to describe the clinical efficacy and safety of a bivalent SARS-CoV-2 recombinant protein vaccine as a two-injection primary series during a period of circulation of the omicron (B.1.1.529) variant. Methods We conducted a phase
-
Broad protection from SARS-CoV-2 variants without antigen matching Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-13 Keith Chappell
Abstract not available
-
Effect of once-per-day tacrolimus versus twice-per-day ciclosporin on 3-year incidence of chronic lung allograft dysfunction after lung transplantation in Scandinavia (ScanCLAD): a multicentre randomised controlled trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-10 Göran Dellgren, Thomas Kromann Lund, Peter Raivio, Inga Leuckfeld, Johan Svahn, Erik C Holmberg, Peter Skov Olsen, Maija Halme, Arnt Fiane, Sandra Lindstedt, Gerdt C Riise, Jesper Magnusson
Background Evidence is low regarding the choice of calcineurin inhibitor for immunosuppression after lung transplantation. We aimed to compare the use of tacrolimus once per day with ciclosporin twice per day according to the current definition of chronic lung allograft dysfunction (CLAD) after lung transplantation. Methods ScanCLAD is an investigator-initiated, open-label, multicentre, randomised
-
Once-per-day tacrolimus to reduce chronic lung transplant rejection Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-10 Michael P Combs
Abstract not available
-
End-of-life care in cystic fibrosis in the era of new therapies Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-09 Elisabeth P Dellon, Jessica Goggin
Abstract not available
-
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-09 Nicole Mayer-Hamblett, John Paul Clancy, Raksha Jain, Scott H Donaldson, Isabelle Fajac, Christopher H Goss, Deepika Polineni, Felix Ratjen, Bradley S Quon, Edith T Zemanick, Scott C Bell, Jane C Davies, Manu Jain, Michael W Konstan, Natanya R Kerper, Tré LaRosa, Marcus A Mall, Edward McKone, Kelsie Pearson, Joseph M Pilewski, Damian G Downey
The growing use of modulator therapies aimed at restoring cystic fibrosis transmembrane conductance regulator (CFTR) protein function in people with cystic fibrosis has fundamentally altered clinical trial strategies needed to advance new therapeutics across an orphan disease population that is now divided by CFTR modulator eligibility. The development of a robust pipeline of nucleic acid-based therapies
-
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-09 Katherine B Hisert, Susan E Birket, John Paul Clancy, Damian G Downey, John F Engelhardt, Isabelle Fajac, Robert D Gray, Marrah E Lachowicz-Scroggins, Nicole Mayer-Hamblett, Patrick Thibodeau, Katherine L Tuggle, Claire E Wainwright, Kris De Boeck
Cystic fibrosis is a multiorgan disease caused by impaired function of the cystic fibrosis transmembrane conductance regulator (CFTR). Since the introduction of the CFTR modulator combination elexacaftor–tezacaftor–ivacaftor (ETI), which acts directly on mutant CFTR to enhance its activity, most people with cystic fibrosis (pwCF) have seen pronounced reductions in symptoms, and studies project marked
-
Trial emulation with observational data in cystic fibrosis Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-09 Gwyneth Davies, Ruth H Keogh
Abstract not available
-
Earlier start to COVID-19 autumn vaccine programmes Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-08 Talha Burki
Abstract not available
-
COPD and multimorbidity: recognising and addressing a syndemic occurrence Lancet Respir. Med. (IF 76.2) Pub Date : 2023-09-08 Leonardo M Fabbri, Bartolome R Celli, Alvar Agustí, Gerard J Criner, Mark T Dransfield, Miguel Divo, Jamuna K Krishnan, Lies Lahousse, Maria Montes de Oca, Sundeep S Salvi, Daiana Stolz, Lowie E G W Vanfleteren, Claus F Vogelmeier
Most patients with chronic obstructive pulmonary disease (COPD) have at least one additional, clinically relevant chronic disease. Those with the most severe airflow obstruction will die from respiratory failure, but most patients with COPD die from non-respiratory disorders, particularly cardiovascular diseases and cancer. As many chronic diseases have shared risk factors (eg, ageing, smoking, pollution
-
Primary ciliary dyskinesia treatment: time for a new approach? Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-31 Marco Maglione, Antonella Tosco, Melissa Borrelli, Francesca Santamaria
Abstract not available
-
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-31 Felix C Ringshausen, Adam J Shapiro, Kim G Nielsen, Henryk Mazurek, Massimo Pifferi, Karl H Donn, Menno M van der Eerden, Michael R Loebinger, Maimoona A Zariwala, Margaret W Leigh, Michael R Knowles, Thomas W Ferkol
Background Mucociliary clearance is dysfunctional in people with primary ciliary dyskinesia, resulting in the accumulation of dehydrated mucus in the airways that is difficult to clear. We undertook a study to assess the benefit on lung function of treatment with a nebulised epithelial sodium channel (ENaC) blocker, idrevloride, with or without hypertonic saline, in people with primary ciliary dyskinesia
-
Detecting hypoxaemia among children with pneumonia in low-resource settings Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-30 Shams El Arifeen, Aniqa Tasnim Hossain, Ahmed Ehsanur Rahman
Abstract not available
-
From profit to impact: lives saved and the future of RSV vaccine development Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-30 Natalie Mazur, Yvette Löwensteyn
Abstract not available
-
Natalie Mazur—creating an affordable vaccine for RSV Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-30 Tony Kirby
Abstract not available
-
Coal-fired power plant pollution in South Africa Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-24 Munyaradzi Makoni
Abstract not available
-
Identifying molecular phenotypes in sepsis: an analysis of two prospective observational cohorts and secondary analysis of two randomised controlled trials Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-23 Pratik Sinha, V Eric Kerchberger, Andrew Willmore, Julia Chambers, Hanjing Zhuo, Jason Abbott, Chayse Jones, Nancy Wickersham, Nelson Wu, Lucile Neyton, Charles R Langelier, Eran Mick, June He, Alejandra Jauregui, Matthew M Churpek, Antonio D Gomez, Carolyn M Hendrickson, Kirsten N Kangelaris, Aartik Sarma, Aleksandra Leligdowicz, Carolyn S Calfee
Background In sepsis and acute respiratory distress syndrome (ARDS), heterogeneity has contributed to difficulty identifying effective pharmacotherapies. In ARDS, two molecular phenotypes (hypoinflammatory and hyperinflammatory) have consistently been identified, with divergent outcomes and treatment responses. In this study, we sought to derive molecular phenotypes in critically ill adults with sepsis
-
Beyond patterns: how to assign biological meaning to ARDS and sepsis phenotypes Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-23 Harm-Jan de Grooth, Olaf L Cremer
Abstract not available
-
Seeing the funny side of anaesthetics Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-23 Peter Ranscombe
Abstract not available
-
Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-14 Karen M Olsson, Tamera J Corte, Jan C Kamp, David Montani, Steven D Nathan, Lavinia Neubert, Laura C Price, David G Kiely
Patients with chronic lung diseases, particularly interstitial lung disease and chronic obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in clinical deterioration, worsening of oxygen uptake, and an increased mortality risk. Pulmonary hypertension can develop and progress independently from the underlying lung disease. The pulmonary vasculopathy is distinct from
-
New developments in bronchiectasis Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-14
Abstract not available
-
Illuminating the many faces of pulmonary hypertension Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-14 Joseph Newman, Joanna Pepke-Zaba
Abstract not available
-
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-14 Marion Delcroix, Marc de Perrot, Xavier Jaïs, David P Jenkins, Irene M Lang, Hiromi Matsubara, Lilian J Meijboom, Rozenn Quarck, Gérald Simonneau, Christoph B Wiedenroth, Nick H Kim
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism. Important advances have enabled better understanding, characterisation, and treatment of this condition. Guidelines recommending systematic follow-up after acute pulmonary embolism, and the insight that CTEPH can mimic acute pulmonary embolism on initial presentation, have led to the definition
-
Treatment of pulmonary arterial hypertension: recent progress and a look to the future Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-14 Marc Humbert, Olivier Sitbon, Christophe Guignabert, Laurent Savale, Athénaïs Boucly, Mélanie Gallant-Dewavrin, Vallerie McLaughlin, Marius M Hoeper, Jason Weatherald
Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic science discoveries, randomised controlled trials, studies of real-world data, and the development of clinical practice guidelines, considerable progress has been made in the treatment options and outcomes for patients with PAH,
-
Global efforts to improve tuberculosis drug availability Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-11 Talha Burki
Abstract not available
-
Holding out for a hero Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-09 Peter Ranscombe
Abstract not available
-
Germany's cycling vision threatened by proposed budget cuts Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-04 Vijay Shankar Balakrishnan
Abstract not available
-
HLA-B*15:01 allele and asymptomatic SARS-CoV-2 infection Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-04 Marcia Triunfol
Abstract not available
-
Influenza deaths for the 2022–23 season Lancet Respir. Med. (IF 76.2) Pub Date : 2023-08-03 Priya Venkatesan
Abstract not available
-
Developments and priorities in bronchiectasis research Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-31 Oleksandr Mazulov, Adam T Hill, Julie Marchant
Abstract not available
-
Correction to Lancet Respir Med 2023; 11: 453–64 Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-31
Abstract not available
-
Health warnings to be put on individual cigarettes in Canada Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-31 Tony Kirby
Abstract not available
-
Alex Mazulov—battling bronchiectasis in wartime Ukraine Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-31 Tony Kirby
Abstract not available
-
Long COVID: confronting a growing public health crisis Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-19
Abstract not available
-
Correction to Lancet Respir Med 2018; 6: e29 Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-19
Abstract not available
-
Long COVID—unravelling a complex condition Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-17 Carol L Hodgson, Tessa Broadley
Abstract not available
-
Mitigating neurological, cognitive, and psychiatric sequelae of COVID-19-related critical illness Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-17 Pratik Pandharipande, Shawniqua Williams Roberson, Fiona E Harrison, Jo Ellen Wilson, Julie A Bastarache, E Wesley Ely
Despite advances in the treatment and mitigation of critical illness caused by infection with SARS-CoV-2, millions of survivors have a devastating, post-acute infection syndrome known as long COVID. A large proportion of patients with long COVID have nervous system dysfunction, which is also seen in the distinct but overlapping condition of post-intensive care syndrome (PICS), putting survivors of
-
Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-17 Matteo Parotto, Mariann Gyöngyösi, Kathryn Howe, Sheila N Myatra, Otavio Ranzani, Manu Shankar-Hari, Margaret S Herridge
Individuals with SARS-CoV-2 infection can develop symptoms that persist well beyond the acute phase of COVID-19 or emerge after the acute phase, lasting for weeks or months after the initial acute illness. The post-acute sequelae of COVID-19, which include physical, cognitive, and mental health impairments, are known collectively as long COVID or post-COVID-19 condition. The substantial burden of this
-
Ultra-low tidal volume ventilation for lung protection: not so fast Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-12
Abstract not available
-
Ultra-low tidal volume ventilation for COVID-19-related ARDS in France (VT4COVID): a multicentre, open-label, parallel-group, randomised trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-12
Background COVID-19-related acute respiratory distress syndrome (ARDS) is associated with a high mortality rate and longer mechanical ventilation. We aimed to assess the effectiveness of ventilation with ultra-low tidal volume (ULTV) compared with low tidal volume (LTV) in patients with COVID-19-related ARDS. Methods This study was a multicentre, open-label, parallel-group, randomised trial conducted
-
Intensive care unit delirium—a decade of learning Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-04 Katarzyna Kotfis, E Wesley Ely, Yahya Shehabi
Abstract not available
-
Correction to Lancet Respir Med 2022; 10: e63–64 Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-04
Abstract not available
-
Katarzyna Kotfis—putting ICU delirium on the map Lancet Respir. Med. (IF 76.2) Pub Date : 2023-07-04 Tony Kirby
Abstract not available
-
The law of unintended consequences: the crutch of video laryngoscopy Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-26 Kumaran Senthil, Rodrigo J Daly Guris, Laszlo Vutskits, Justin L Lockman
Abstract not available
-
Addressing the origins and health effects of small lungs Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-21 Magnus Ekström, Helena Backman, David Mannino
Abstract not available
-
Addressing the origins and health effects of small lungs – Authors' reply Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-21 Peter Burney, Ben Knox-Brown, André F S Amaral
Abstract not available
-
A negative trial for vasoactive intestinal peptide in COVID-19-associated acute hypoxaemic respiratory failure Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-19 Warren L Lee, Arthur S Slutsky
Abstract not available
-
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-19 Samuel M Brown, Christina E Barkauskas, Birgit Grund, Shweta Sharma, Andrew N Phillips, Lindsay Leither, Ithan D Peltan, Michael Lanspa, Daniel L Gilstrap, Ahmad Mourad, Kathleen Lane, Jeremy R Beitler, Alexis L Serra, Ivan Garcia, Eyad Almasri, Mohamed Fayed, Kinsley Hubel, Estelle S Harris, Elizabeth A Middleton, Macy A G Barrios, Christine Wenner
Background There is a clinical need for therapeutics for COVID-19 patients with acute hypoxemic respiratory failure whose 60-day mortality remains at 30-50%. Aviptadil, a lung-protective neuropeptide, and remdesivir, a nucleotide prodrug of an adenosine analog, were compared with placebo among patients with COVID-19 acute hypoxaemic respiratory failure. Methods TESICO was a randomised trial of aviptadil
-
Managing medical (mis)information Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-19
Abstract not available
-
Cough and cough hypersensitivity as treatable traits of asthma Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-16 Kefang Lai, Imran Satia, Woo-Jung Song, Gang Wang, Akio Niimi, Philip Pattemore, Anne B Chang, Peter G Gibson, Kian Fan Chung
Cough is a common and troublesome symptom in people with asthma and is often associated with poorer asthma control and exacerbations. Apart from asthma, other causes or comorbidities might underlie cough in asthma, such as rhinosinusitis and bronchiectasis. Eosinophilic inflammation and bronchoconstriction can lead to an acute episode of cough or worsen chronic cough. Cough hypersensitivity with laryngeal
-
Reducing treatment burden in the era of CFTR modulators – Authors' reply Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-12 Alex H Gifford, Nicole Mayer-Hamblett, David P Nichols
Abstract not available
-
Reducing treatment burden in the era of CFTR modulators Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-12 Paul D Robinson, Tonia A Douglas, Claire E Wainwright
Abstract not available
-
Inhibiting C5 in patients with severe COVID-19—the incorrect target? Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-09 Endry H T Lim, Alexander P J Vlaar, Matthijs C Brouwer, Diederik van de Beek
Abstract not available
-
Inhibiting C5 in patients with severe COVID-19—the incorrect target? – Authors’ reply Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-09 Djillali Annane, Sean J Pittock, Derek Dunn, Austin Kulasekararaj
Abstract not available
-
2023 GINA report for asthma Lancet Respir. Med. (IF 76.2) Pub Date : 2023-06-08 Priya Venkatesan
Abstract not available
更新日期：2023-09-23
Copyright © 2014-2023 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495-2号
京公网安备 11010802027423号
京公网安备 11010802027423号